FINWIRES · TerminalFinancial News · Live TerminalLIVE

SHA:688506

17 stories mentioning SHA:688506Updated 3d ago

Every FINWIRES story that references SHA:688506, newest first.

Sichuan Biokin Pharmaceutical Enrolls First Subject in Phase 3 Trial for Biliary Tract Cancer Treatment

Sichuan Biokin Pharmaceutical (SHA:688506) enrolled the first subject of its phase 3 clinical trial for its T-Bren injection in patients with biliary tract cancer, according to a Monday filing with the Shanghai Stock Exchange.The drug is indicated for patients with HER2-expressing locally advanced or metastatic biliary tract cancer who have failed platinum-based chemotherapy.T-Bren is also undergoing 19 clinical trials locally and abroad, including eight phase 3 trials, one phase 2/3 trial, four phase 2 trials, three phase 1/2 trials, and three phase 1 trials for diseases covering breast cancer, gastric or gastroesophageal junction adenocarcinoma, and non-small cell lung cancer.Shares rose 1% during the midday break on Monday.

Biokin Pharma Enrolls First Subject in Phase III Clinical Trial of Breast Cancer Drug

Sichuan Biokin Pharmaceutical (SHA:688506) enrolled its first patient for the phase III clinical trial of loncastuximab/izabren, according to a Friday disclosure on the Shanghai bourse.The drug is being tested as a treatment for unresectable locally advanced, recurrent, or metastatic HR+/HER2− breast cancer whose disease has progressed following endocrine therapy.The Chinese pharmaceutical company's shares fell 4% during the morning trade.

Sichuan Biokin Pharmaceutical's ADC Enters Phase Three Trial for Biliary Tract Cancer

Sichuan Biokin Pharmaceutical (SHA:688506) said the first patient for its third-phase randomized controlled clinical trial has been dosed, according to a Friday filing with the Shanghai bourse.The trial is evaluating the company's flagship EGFR×HER3 bispecific antibody drug conjugate (ADC), Lunka Yilong Tuodan/Yizekang, for locally advanced or metastatic biliary tract cancer after platinum chemotherapy failure.Shares of the pharmaceutical company were down 4% in recent trade.

Sichuan Biokin Pharmaceutical Secures Drug Registration Certificate for Esophageal Cancer Drug; Shares Fall 8%

Sichuan Biokin Pharmaceutical (SHA:688506) received a drug registration certificate from China's National Medical Products Administration for its independently developed Elontuzumab/Iza-bren, according to a Friday filing with the Shanghai bourse.The antibody drug conjugate is indicated for advanced esophageal cancer and is the second indication for the drug approved in China.Shares fell 8% during the midday break on Friday.

Biokin Pharma Enrolls First Subject for Phase III Trial for Iza-Bren As Lung Cancer Treatment; Shares Down 5%

Sichuan Biokin Pharmaceutical (SHA:688506) enrolled the first subject in its Phase III clinical trial for BL-B01D1/iza-bren as a treatment for extensive-stage small cell lung cancer, according to a Shanghai bourse filing on Friday.The drug is being tested in combination with a PD-1 monoclonal antibody versus platinum-based chemotherapy in combination with a PD-1 monoclonal antibody.The pharmaceutical company's shares dropped 5% during the morning trade.

Sichuan Biokin Pharmaceutical Gets China Nod for Anti-Cancer Drug

Sichuan Biokin Pharmaceutical (SHA:688506) obtained drug registration from China's medical products regulator for the market launch of lunkang yilong tuomab injection.The drug, brand name Yizekang, is indicated for recurrent/metastatic nasopharyngeal carcinoma patients, according to a Tuesday filing with the Shanghai bourse.Shares of the pharmaceutical company were up 11% in recent trade.

Sichuan Biokin Pharmaceutical Gets China Nod for Lung Cancer Combo Trial

Sichuan Biokin Pharmaceutical (SHA:688506) received China's regulatory approval to conduct clinical trials of its BL-M14D1 injection.The clinical trials will focus on the drug in combination with PD-1/PD-L1 inhibitors for extensive-stage small cell lung cancer, according to a Monday filing with the Shanghai bourse.Shares of the drugmaker were up 1% in recent trade.

Sichuan Biokin Pharmaceutical's Breast Cancer Drug Gets Accepted for Review; Shares Up 3%

Sichuan Biokin Pharmaceutical (SHA:688506) said China's Center for Drug Evaluation has accepted the new drug application for iza-bren for treating breast cancer.The submission follows a Phase Three trial where iza-bren met dual primary endpoints of progression-free and overall survival, according to a Monday filing with the Shanghai bourse.Shares of the drugmaker were up 3% in recent trade.

Biokin Pharma Gets Nod to Trial BL-M14D1 With Other Therapies

Sichuan Biokin Pharmaceutical (SHA:688506) received approval from China's National Medical Products Administration for the clinical trials of combination therapies with the drug, BL-M14D1 (DLL3ADC), according to a Shanghai bourse filing on Monday.The regulator allows the drug to be tested with PD-L1 monoclonal antibodies, anti-angiogenic agents and chemotherapy for the treatment of small cell lung cancer.The drugmaker's shares rose 2% during the morning trade Monday.

Sichuan Biokin Pharmaceutical Gets US FDA Clearance for Lung Cancer Drug Trial

Sichuan Biokin Pharmaceutical (SHA:688506) obtained clearance from the U.S. Food and Drug Administration for its Phase Three clinical trial application for BL-M14D1 combined with immunotherapy as a first-line treatment for extensive-stage small cell lung cancer, according to a Tuesday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 1% in recent trade.

Sichuan Biokin Pharmaceutical Secures Commitment for Share Repurchase Loan

Sichuan Biokin Pharmaceutical (SHA:688506) obtained a commitment letter for a 180 million yuan, three-year loan from Bank of China (HKG:3988, SHA:601988) for its share repurchase program, according to a Saturday filing with the Shanghai bourse.The drug company plans to repurchase between 100 million yuan and 200 million yuan of shares at 398 yuan apiece.

HKG:3988SHA:601988SHA:688506

Sichuan Biokin Pharmaceutical Secures China Clinical Trial Approval for Lymphoma Injection

China's drug regulator approved Sichuan Biokin Pharmaceutical's (SHA:688506) clinical trial for its BL-M08D1 injection as a combination therapy for diffuse large B-cell lymphoma, according to a Friday filing with the Shanghai bourse.Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma, according to the Mayo Clinic.BL-M08D1 is also undergoing phase 1B trials for relapsed or refractory hematologic malignancies and locally advanced tumors.

Biokin Pharmaceutical Enrolls First Subject for Phase III Trial for BL-M05D1

Sichuan Biokin Pharmaceutical (SHA:688506) completed the enrollment of its first subject in the Phase III clinical trial on BL-M05D1 injection, according to a Shanghai bourse filing on Friday.The drug is being tested as a treatment for patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma who have previously received first-line therapy.

Biokin Pharma Gets Nod to Trial Iza-Bren Drug Combination for Lung Cancer

Sichuan Biokin Pharmaceutical (SHA:688506) received approval from China's National Medical Products Administration for the clinical trial of a combination therapy with iza-bren for injection (BL-B01D1), according to a Shanghai bourse filing on Wednesday.The drug will be tested in combination with small-molecule targeted therapies for the treatment of non-small cell lung cancer.

Biokin Pharma Enrolls First Subject for T-Bren's Phase III Trial

Sichuan Biokin Pharmaceutical (SHA:688506) enrolled the first subject for the Phase III clinical trial of T-Bren, according to a Shanghai bourse filing on Wednesday.The drug is being tested in combination with pertuzumab and trastuzumab for the treatment of HER2-positive recurrent or metastatic breast cancer.

Sichuan Biokin Pharma Posts 128% Profit Drop in 2025 as Revenue Halves; Shares Down 3%

Sichuan Biokin Pharmaceutical (SHA:688506) reported a 128% decrease in net profit in 2025 to 1.05 billion yuan from 3.71 billion yuan a year earlier.Earnings per share plunged to 2.61 yuan from 9.25 yuan, the pharmaceutical company said in a Shanghai bourse filing on Tuesday.Revenue slumped 57% to 2.52 billion yuan from 5.82 billion yuan.Biokin attributed the lackluster performance to a high comparison base as the revenue generated in 2024 benefited from the intellectual property cooperation agreement it reached with BMS on a product called Iza-bren.Shares of the company fell 3% in recent trade.

Sichuan Biokin Pharma's Q1 Loss Balloons Despite Revenue Growth; Shares Up 3%

Sichuan Biokin Pharmaceutical's (SHA:688506) attributable net loss ballooned to 774.6 million yuan in the first quarter from 531.4 million yuan a year earlier.Loss per share likewise widened to 1.88 yuan from 1.33 yuan, the pharmaceutical company said in a Shanghai bourse filing on Tuesday.Revenue, however, jumped 40% to 94.6 million yuan from 67.4 million yuan, which Biokin attributed to increased market demand for its products.Shares of the company fell nearly 3% in recent trade.

Track with the FINWIRES app suite

Track SHA:688506 in your portfolio

Analyze SHA:688506 options with the wheel strategy

See market sentiment on SHA:688506

SHA:688506 News | FINWIRES